Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease
- 293 Downloads
Patients with non-valvular atrial fibrillation (NVAF) and chronic kidney disease (CKD) are at increased risk of stroke and bleeding. Although direct oral anticoagulant (DOAC) trials excluded patients with severe CKD, a growing portion of CKD patients have been starting DOACs and limited data from real-world outcome in this high-risk setting are available. The INSigHT registry included 632 consecutive NVAF patients that started apixaban (256 patients, 41%), dabigatran (245, 39%) and rivaroxaban (131, 20%) between 2012 and 2015. Based on creatinine clearance, two sub-cohorts were defined: (1) non-CKD group (CrCl 60–89 mL/min, 413 patients) and (2) CKD group (15–59 ml/min, 219). Compared to non-CKD patients, those with CKD, were at higher ischemic (CHA2DS2-VASc 4.5 vs 2.9, p < 0.001) and hemorrhagic risk (HAS-BLED 2.4 vs 1.8, p < 0.001). At 2-year follow-up, the overall ISTH-major bleeding and thromboembolic event rates were 5.2% and 2.3% and no significant difference between non-CKD and CKD patients for both efficacy and safety endpoints were observed. In non-CKD patients, the 2-year ISTH-major bleeding rates were higher in rivaroxaban group (HR 2.9, 95% CI 1.1–7.3; p = 0.047) while dabigatran showed non-significant excess in thromboembolic events (HR 4.3, 95% CI 0.9–20.8; p = 0.068). In CKD patients, a significantly higher rate of thromboembolic events was observed in rivaroxaban (HR 6.3, 95% CI 1.1–38.1; p = 0.044). This real-world, non-insurance database registry shows remarkable 2-year safety and efficacy profile of DOACs even in patients with moderate to severe CKD. Head to head differences between DOACs are exploratory, hypothesis generating and warrant further investigation in larger studies.
KeywordsNon-valvular atrial fibrillation Direct oral anticoagulant Chronic kidney disease
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflict of interest.
Statement of human and animal rights
The study was in accordance with the ethical standards of the institutional research committee.
All patients provided informed consent for data collection.
- 1.Das M, Aronow WS, McClung JA, Belkin RN (2006) Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol Rev 14:14–17. https://doi.org/10.1097/01.crd.0000148162.88296.9f CrossRefGoogle Scholar
- 3.Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation:the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369. https://doi.org/10.1161/CIRCULATIONAHA.108.816082 CrossRefGoogle Scholar
- 5.Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB (2015) Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease. J Am Coll Cardiol 64:2471–2482. https://doi.org/10.1016/j.jacc.2014.09.051 CrossRefGoogle Scholar
- 9.Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB (2015) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol. 5:418–429. https://doi.org/10.1007/s00392-014-0797-9 CrossRefGoogle Scholar
- 10.Heidbuchel H, Verhamme P, Alings M et al (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 38(27):2137–2149. https://doi.org/10.1093/eurheartj/ehw058 Google Scholar
- 11.Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. The BMJ 365:1–10. https://doi.org/10.1136/bmj.j510 Google Scholar
- 21.Conover WJ (1999) Practical nonparametric statistics, 3rd edn. Wiley, New YorkGoogle Scholar
- 24.Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt UY, Hebert LA (2011) Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 80:181–189. https://doi.org/10.1038/ki.2011.44 CrossRefGoogle Scholar
- 25.Brodsky SV, Collins M, Park E, Rovin BH, Satoskar AA, Nadasdy G, Wu H, Bhatt U, Nadasdy T, Hebert LA (2010) Warfarin therapy that results in an international normalization ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 115(2):c142–c146. https://doi.org/10.1159/000312877 CrossRefGoogle Scholar
- 26.Böhm M, Ezekowitzet M, Connolly S, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L (2015) Changes in renal function in patients with atrial fibrillation an analysis from the RE-LY trial. J Am Coll Cardiol 65(23):2481–2493. https://doi.org/10.1016/j.jacc.2015.03.577 CrossRefGoogle Scholar
- 27.Insights From ROCKET AF, On-Treatment Outcomes in Patients with Worsening Renal Function with Rivaroxaban Compared with Warfarin (2016) On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with Warfarin: Insights From ROCKET AF. Circulation 2016(1):37–47. https://doi.org/10.1161/CIRCULATIONAHA.116.021890
- 30.Loo SY, Coulombe J, Dell'Aniello S, Brophy JM, Suissa S, Renoux C (2018) Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ 8:1–10. https://doi.org/10.1136/bmjopen-2017-019638 Google Scholar
- 32.Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L (2014) Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 129:961–970. https://doi.org/10.1161/CIRCULATIONAHA.113.003628 CrossRefGoogle Scholar
- 33.Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:2821–2830. https://doi.org/10.1093/eurheartj/ehs274 CrossRefGoogle Scholar
- 34.Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32:2387–2394. https://doi.org/10.1093/eurheartj/ehr342 CrossRefGoogle Scholar
- 37.Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N (2015) Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 113:1247–1257. https://doi.org/10.1160/TH14-11-0954 CrossRefGoogle Scholar
- 38.Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG (2016) XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37:1145–1153. https://doi.org/10.1093/eurheartj/ehv466 CrossRefGoogle Scholar
- 39.Vedovati MC, Verdecchia P, Giustozzi M, Molini G, Conti S, Pierpaoli L, Valecchi F, Aita A, Agnelli G, Becattini C (2017) Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. Int J Cardiol 236:363–369. https://doi.org/10.1016/j.ijcard.2017.01.098 CrossRefGoogle Scholar